Last mentioned: Feb 26, 2026
The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for the 2025 fiscal year, balancing immediate commercial headwinds with aggressive long-term guidance. Both companies introduced fiscal year 2026 outlooks, signaling a strategic shift toward post-2025 growth catalysts and pipeline diversification.
Delcath Systems, Lantheus Holdings, Butterfly Network, and Heron Therapeutics are preparing to report Q4 2025 earnings, marking a critical test for commercial-stage medical innovators. Investors are laser-focused on the adoption rates of flagship products like HEPZATO KIT and PYLARIFY as these companies navigate a complex reimbursement environment.
This page surfaces every story mentioning Heron Therapeutics across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Heron Therapeutics was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |